Effect of ambrisentan on echocardiographic and Doppler measures from patients in China with pulmonary arterial hypertension.

Qin-Hua ZhaoFu-Hua PengZai-Xin YuGang-Cheng ZhangQiu-Shang JiYong WangJin-Ming LiuYong HuoXiao-Feng ZengJian-Hui LiLu ZiZhi-Cheng Jing

Published in: Expert review of cardiovascular therapy (2020)

Significant improvements in a number of RV echocardiographic parameters were observed at Weeks 12 and 24 after ambrisentan treatment in patients with PAH.

Keyphrases

pulmonary arterial hypertension
pulmonary hypertension
ejection fraction
end stage renal disease
pulmonary artery
left ventricular
mycobacterium tuberculosis
newly diagnosed
mitral valve
chronic kidney disease
left atrial
prognostic factors
peritoneal dialysis
patient reported outcomes
blood flow